Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:CALTNASDAQ:GLUENASDAQ:IOVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$23.88-2.2%$26.63$22.64▼$53.96$1.13B0.79465,890 shs562,390 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGLUEMonte Rosa Therapeutics$4.90-0.2%$5.23$3.21▼$12.40$301.40M1.531.05 million shs286,243 shsIOVAIovance Biotherapeutics$3.33-7.2%$3.61$2.70▼$14.23$1.09B1.057.63 million shs10.84 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.37%+3.61%-15.80%-32.88%-40.82%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+106.08%GLUEMonte Rosa Therapeutics+2.51%-7.88%+5.82%-23.88%-7.71%IOVAIovance Biotherapeutics+0.84%+12.54%+7.81%-42.19%-69.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.505 of 5 stars3.03.00.03.73.54.21.3CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AGLUEMonte Rosa Therapeutics1.9755 of 5 stars3.40.00.00.02.13.30.6IOVAIovance Biotherapeutics4.567 of 5 stars4.43.00.04.22.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.00Hold$43.5082.16% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50216.33% UpsideIOVAIovance Biotherapeutics 2.89Moderate Buy$18.22447.21% UpsideCurrent Analyst Ratings BreakdownLatest GLUE, CALT, IOVA, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $16.004/14/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $5.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.003/21/2025GLUEMonte Rosa TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $10.003/20/2025GLUEMonte Rosa TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.003/12/2025GLUEMonte Rosa TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.003/3/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $15.003/3/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.003/3/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $30.002/28/2025IOVAIovance BiotherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$24.00 ➝ $20.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.55$3.33 per share7.17$13.35 per share1.79CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GLUEMonte Rosa Therapeutics$75.62M3.99N/AN/A$3.58 per share1.37IOVAIovance Biotherapeutics$164.07M6.65N/AN/A$2.28 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$3.067.967.262.1921.80%26.44%11.89%5/6/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGLUEMonte Rosa Therapeutics-$135.35M-$1.02N/AN/AN/AN/A-62.68%-38.83%5/8/2025 (Estimated)IOVAIovance Biotherapeutics-$444.04M-$1.30N/AN/AN/A-451.25%-58.43%-45.48%5/8/2025 (Estimated)Latest GLUE, CALT, IOVA, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025AMPHAmphastar Pharmaceuticals$0.66N/AN/AN/A$173.29 millionN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24N/AN/AN/A$13.57 millionN/A5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25N/AN/AN/A$83.40 millionN/A3/20/2025Q4 2024GLUEMonte Rosa Therapeutics-$0.37$0.23+$0.60$0.23$43.73 million$14.00 million2/27/2025Q4 2024IOVAIovance Biotherapeutics-$0.26-$0.26N/A-$0.26$72.17 million$73.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61CALTCalliditas Therapeutics AB (publ)9.442.692.59GLUEMonte Rosa TherapeuticsN/A6.036.03IOVAIovance BiotherapeuticsN/A4.223.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CALTCalliditas Therapeutics AB (publ)2.83%GLUEMonte Rosa Therapeutics79.96%IOVAIovance Biotherapeutics77.03%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%CALTCalliditas Therapeutics AB (publ)2.20%GLUEMonte Rosa Therapeutics6.50%IOVAIovance Biotherapeutics12.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.44 millionOptionableIOVAIovance Biotherapeutics500327.88 million267.90 millionOptionableGLUE, CALT, IOVA, and AMPH HeadlinesRecent News About These Companies2 Beaten-Down Stocks With Incredible Upside PotentialApril 30 at 5:14 AM | fool.com2MDXG : A Peek at MiMedx Group's Future EarningsApril 29 at 6:36 PM | benzinga.comHood River Capital Management LLC Grows Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 25, 2025 | marketbeat.comLong Focus Capital Management LLC Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 25, 2025 | marketbeat.comMarshall Wace LLP Invests $8.37 Million in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 25, 2025 | marketbeat.comTumor-infiltrating lymphocyte therapy effective against common gastrointestinal cancersApril 24, 2025 | healio.comIovance Biotherapeutics Announces Participation in Upcoming Scientific CongressesApril 23, 2025 | globenewswire.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.6% - Here's WhyApril 23, 2025 | marketbeat.comCommit To Buy Iovance Biotherapeutics At $2.50, Earn 35.1% Annualized Using OptionsApril 23, 2025 | nasdaq.comAvoro Capital Advisors LLC Trims Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 23, 2025 | marketbeat.com992,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by B Group Inc.April 23, 2025 | marketbeat.comIovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.April 23, 2025 | fool.comIovance Biotherapeutics: Only For The BraveApril 22, 2025 | seekingalpha.comThis Biotech Stock Could Be the Best Investment of the DecadeApril 19, 2025 | fool.comIs Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?April 18, 2025 | insidermonkey.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)April 18, 2025 | globenewswire.comCapital Fund Management S.A. Lowers Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 18, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.9% on Analyst DowngradeApril 17, 2025 | marketbeat.comIs Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $5.00 at BarclaysApril 16, 2025 | marketbeat.comGeode Capital Management LLC Raises Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUE, CALT, IOVA, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$23.88 -0.53 (-2.17%) Closing price 04:00 PM EasternExtended Trading$23.87 -0.01 (-0.04%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 04/28/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Monte Rosa Therapeutics NASDAQ:GLUE$4.90 -0.01 (-0.20%) Closing price 04:00 PM EasternExtended Trading$4.89 -0.01 (-0.10%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$3.33 -0.26 (-7.24%) Closing price 04:00 PM EasternExtended Trading$3.34 +0.00 (+0.15%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
